SC 13G/A 1 w04891sc13gza.htm SCHEDULE 13G/A - AMENDMENT NO. 1 sc13gza
 

OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response...11


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

LIGAND PHARMACEUTICALS INCORPORATED

(Name of Issuer)

Common Stock, $.001 par value

(Title of Class of Securities)

53220K207

(Cusip Number)

January 14, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

        o Rule 13d-1 (b)

        x Rule 13d-1 (c)

        o Rule 13d-1 (d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

Page 1 of 6

 

             
CUSIP No. 53220K207
  1. Name of Reporting Person:
BB Biotech AG		 I.R.S. Identification Nos. of above persons (entities only):
N/A
  2. Check the Appropriate Box if a Member of a Group:
    (a) x  
    (b) o  
  3. SEC Use Only:
  4. Citizenship or Place of Organization:
Switzerland
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power:
0
6. Shared Voting Power:
3,655,400
7. Sole Dispositive Power:
0
8.Shared Dispositive Power:
3,655,400
  9.Aggregate Amount Beneficially Owned by Each Reporting Person:
3,655,400
  10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares:
o
  11.Percent of Class Represented by Amount in Row (9):
4.9%
  12.Type of Reporting Person:
HC, CO

Page 2 of 6

 

             
CUSIP No. 53220K207
  1. Name of Reporting Person:
Biotech Invest N.V.		 I.R.S. Identification Nos. of above persons (entities only):
N/A
  2. Check the Appropriate Box if a Member of a Group:
    (a) x  
    (b) o  
  3. SEC Use Only:
  4. Citizenship or Place of Organization:
Netherlands Antilles
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power:
0
6. Shared Voting Power:
3,655,400
7. Sole Dispositive Power:
0
8.Shared Dispositive Power:
3,655,400
  9.Aggregate Amount Beneficially Owned by Each Reporting Person:
3,655,400
  10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares:
o
  11.Percent of Class Represented by Amount in Row (9):
4.9%
  12.Type of Reporting Person:
CO

Page 3 of 6

 

Item 4. Ownership

     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

                     
(a)
  Amount beneficially owned:     3,655,400          
                   
 
                    
(b)
  Percent of class:     4.9 %        
                   
 
                    
(c)
  Number of shares as to which the person has:          
 
                    
  (i) Sole power to vote or to direct the vote       0  
                   
 
                    
  (ii) Shared power to vote or to direct the vote       3,655,400  
                   
 
                    
  (iii) Sole power to dispose or to direct the disposition of       0  
                   
 
                    
  (iv) Shared power to dispose or to direct the disposition of       3,655,400  
                   

Item 5. Ownership of Five Percent or Less of a Class

     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

Item 10. Certification

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 4 of 6

 

SIGNATURES

     After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

             
 
       BB Biotech AG
 
            
Date:
  January 19, 2005   By:   /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
 
            
      Title:   Signatory Authority
           
 
            
Date:
  January 19, 2005   By:   /s/ Adrian Bruengger
           
          Signatory Authority
 
            
      Name:   Adrian Bruengger
           
 
            
      Title:   Signatory Authority
           
 
            
 
       Biotech Invest N.V.
 
            
Date:
  January 19, 2005   By:   /s/ Pascal Schmucki
           
          Signatory Authority
 
            
      Name:   Pascal Schmucki
           
 
            
      Title:   Signatory Authority
           
 
            
Date:
  January 19, 2005   By:   /s/ Adrian Bruengger
           
          Signatory Authority
 
            
      Name:   Adrian Bruengger
           
 
            
      Title:   Signatory Authority
           

Page 5 of 6

 

EXHIBIT INDEX

     
Exhibit 1:
  Agreement by and between BB Biotech and BioInvest with respect to the filing of this disclosure statement.*

*   Previously filed.

Page 6 of 6